Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phase
- Author
- MALOISEL, F1 ; GUERCI, A2 ; ABGRALL, J. F11 ; PEGOURIE-BANDELIER, B12 ; SOLARY, E13 ; CAMBIER, N14 ; COSO, D15 ; VILQUE, J. P16 ; DELAIN, M; HAROUSSEAU, J. L; ROUSSELOT, P; BELHADJ, K; GUYOTAT, D3 ; MORICE, P; ATTAL, J; CHABIN, M; CHASTANG, C; GUILHOT, J; GUILHOT, F; IFRAH, N4 ; MICHALLET, M5 ; REIFFERS, J6 ; TERTAIN, G7 ; BLANC, M8 ; BAUDUER, F9 ; BRIERE, J10
[1] Division of Hematology, University Hospital of Strasbourg, France
[2] Division of Hematology, University Hospital of Nancy, France
[3] Division of Hematology, University Hospital of Saint Etienne, France
[4] Division of Hematology, University Hospital of Angers, France
[5] Division of Hematology, University Hospital of Lyon, France
[6] Division of Hematology, University Hospital of Bordeaux, France
[7] Division of Hematology, University Hospital of Le Kremlin Bicêtre, France
[8] Division of Hematology, University Hospital of Annecy, France
[9] Division of Hematology, University Hospital of Bayonne, France
[10] Division of Hematology, University Hospital of Clichy, France
[11] Division of Hematology, University Hospital of Brest, France
[12] Division of Hematology, Grenoble, France
[13] Division of Hematology, University Hospital of Dijon, France
[14] Division of Hematology, Lille, France
[15] Division of Hematology, Marseille, France
[16] Division of Hematology, University Hospital of Quimper, France
France Intergroupe des Leucémies Myéloïdes Chroniques, France - Source
Leukemia. 2002, Vol 16, Num 4, pp 573-580 ; ref : 25 ref
- CODEN
- LEUKED
- ISSN
- 0887-6924
- Scientific domain
- Medical oncology; Hematology
- Publisher
- Nature Publishing, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Analogue Anticancéreux Antimétabolite Association médicamenteuse Chimiothérapie Chronique Complication Composé lipophile Cytarabine Efficacité traitement Essai clinique phase II Homme Immunothérapie Leucémie myéloïde Promédicament Pyrimidine nucléoside Toxicité Traitement associé Voie orale Interféron alpha 2b YNK01 Cytokine Hémopathie maligne Myéloprolifératif syndrome
- Keyword (en)
- Analog Antineoplastic agent Antimetabolic Drug combination Chemotherapy Chronic Complication Lipophilic compound Cytarabine Treatment efficiency Phase II trial Human Immunotherapy Chronic myelocytic leukemia Prodrug Pyrimidine nucleoside Toxicity Combined treatment Oral administration Interferon alpha 2b Cytokine Malignant hemopathy Myeloproliferative syndrome
- Keyword (es)
- Análogo Anticanceroso Antimetabólito Asociación medicamentosa Quimioterapia Crónico Complicación Compuesto lipófilo Citarabina Eficacia tratamiento Ensayo clínico fase II Hombre Inmunoterapia Leucemia mieloidea Promedicamento Pirimidina nucleósido Toxicidad Tratamiento asociado Vía oral Citoquina Hemopatía maligna Mieloproliferativo síndrome
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R04 Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 13708465
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.leu.2402433 
https://dx.doi.org/10.1038/sj.leu.2402433
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2402433\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon \u03b1-2b for the treatment of chronic myelogenous leukemia patients in chronic phase\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"573\";s:8:\"\u0000*\u0000epage\";s:3:\"580\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MALOISEL\";s:10:\"\u0000*\u0000aufirst\";s:1:\"F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:25:{i:0;s:9:\"GUERCI, A\";i:1;s:13:\"ABGRALL, J. F\";i:2;s:21:\"PEGOURIE-BANDELIER, B\";i:3;s:9:\"SOLARY, E\";i:4;s:10:\"CAMBIER, N\";i:5;s:7:\"COSO, D\";i:6;s:12:\"VILQUE, J. P\";i:7;s:9:\"DELAIN, M\";i:8;s:16:\"HAROUSSEAU, J. L\";i:9;s:12:\"ROUSSELOT, P\";i:10;s:10:\"BELHADJ, K\";i:11;s:10:\"GUYOTAT, D\";i:12;s:9:\"MORICE, P\";i:13;s:8:\"ATTAL, J\";i:14;s:9:\"CHABIN, M\";i:15;s:11:\"CHASTANG, C\";i:16;s:10:\"GUILHOT, J\";i:17;s:10:\"GUILHOT, F\";i:18;s:8:\"IFRAH, N\";i:19;s:12:\"MICHALLET, M\";i:20;s:11:\"REIFFERS, J\";i:21;s:10:\"TERTAIN, G\";i:22;s:8:\"BLANC, M\";i:23;s:10:\"BAUDUER, F\";i:24;s:9:\"BRIERE, J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon \u03b1-2b for the treatment of chronic myelogenous leukemia patients in chronic phase\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2402433\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon \u03b1-2b for the treatment of chronic myelogenous leukemia patients in chronic phase\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"573\";s:8:\"\u0000*\u0000epage\";s:3:\"580\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MALOISEL\";s:10:\"\u0000*\u0000aufirst\";s:1:\"F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:25:{i:0;s:9:\"GUERCI, A\";i:1;s:13:\"ABGRALL, J. F\";i:2;s:21:\"PEGOURIE-BANDELIER, B\";i:3;s:9:\"SOLARY, E\";i:4;s:10:\"CAMBIER, N\";i:5;s:7:\"COSO, D\";i:6;s:12:\"VILQUE, J. P\";i:7;s:9:\"DELAIN, M\";i:8;s:16:\"HAROUSSEAU, J. L\";i:9;s:12:\"ROUSSELOT, P\";i:10;s:10:\"BELHADJ, K\";i:11;s:10:\"GUYOTAT, D\";i:12;s:9:\"MORICE, P\";i:13;s:8:\"ATTAL, J\";i:14;s:9:\"CHABIN, M\";i:15;s:11:\"CHASTANG, C\";i:16;s:10:\"GUILHOT, J\";i:17;s:10:\"GUILHOT, F\";i:18;s:8:\"IFRAH, N\";i:19;s:12:\"MICHALLET, M\";i:20;s:11:\"REIFFERS, J\";i:21;s:10:\"TERTAIN, G\";i:22;s:8:\"BLANC, M\";i:23;s:10:\"BAUDUER, F\";i:24;s:9:\"BRIERE, J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon \u03b1-2b for the treatment of chronic myelogenous leukemia patients in chronic phase\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2402433\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2402433\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon \u03b1-2b for the treatment of chronic myelogenous leukemia patients in chronic phase\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"573\";s:8:\"\u0000*\u0000epage\";s:3:\"580\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MALOISEL\";s:10:\"\u0000*\u0000aufirst\";s:1:\"F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:25:{i:0;s:9:\"GUERCI, A\";i:1;s:13:\"ABGRALL, J. F\";i:2;s:21:\"PEGOURIE-BANDELIER, B\";i:3;s:9:\"SOLARY, E\";i:4;s:10:\"CAMBIER, N\";i:5;s:7:\"COSO, D\";i:6;s:12:\"VILQUE, J. P\";i:7;s:9:\"DELAIN, M\";i:8;s:16:\"HAROUSSEAU, J. L\";i:9;s:12:\"ROUSSELOT, P\";i:10;s:10:\"BELHADJ, K\";i:11;s:10:\"GUYOTAT, D\";i:12;s:9:\"MORICE, P\";i:13;s:8:\"ATTAL, J\";i:14;s:9:\"CHABIN, M\";i:15;s:11:\"CHASTANG, C\";i:16;s:10:\"GUILHOT, J\";i:17;s:10:\"GUILHOT, F\";i:18;s:8:\"IFRAH, N\";i:19;s:12:\"MICHALLET, M\";i:20;s:11:\"REIFFERS, J\";i:21;s:10:\"TERTAIN, G\";i:22;s:8:\"BLANC, M\";i:23;s:10:\"BAUDUER, F\";i:24;s:9:\"BRIERE, J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon \u03b1-2b for the treatment of chronic myelogenous leukemia patients in chronic phase\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2402433\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon \u03b1-2b for the treatment of chronic myelogenous leukemia patients in chronic phase\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"573\";s:8:\"\u0000*\u0000epage\";s:3:\"580\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MALOISEL\";s:10:\"\u0000*\u0000aufirst\";s:1:\"F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:25:{i:0;s:9:\"GUERCI, A\";i:1;s:13:\"ABGRALL, J. F\";i:2;s:21:\"PEGOURIE-BANDELIER, B\";i:3;s:9:\"SOLARY, E\";i:4;s:10:\"CAMBIER, N\";i:5;s:7:\"COSO, D\";i:6;s:12:\"VILQUE, J. P\";i:7;s:9:\"DELAIN, M\";i:8;s:16:\"HAROUSSEAU, J. L\";i:9;s:12:\"ROUSSELOT, P\";i:10;s:10:\"BELHADJ, K\";i:11;s:10:\"GUYOTAT, D\";i:12;s:9:\"MORICE, P\";i:13;s:8:\"ATTAL, J\";i:14;s:9:\"CHABIN, M\";i:15;s:11:\"CHASTANG, C\";i:16;s:10:\"GUILHOT, J\";i:17;s:10:\"GUILHOT, F\";i:18;s:8:\"IFRAH, N\";i:19;s:12:\"MICHALLET, M\";i:20;s:11:\"REIFFERS, J\";i:21;s:10:\"TERTAIN, G\";i:22;s:8:\"BLANC, M\";i:23;s:10:\"BAUDUER, F\";i:24;s:9:\"BRIERE, J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon \u03b1-2b for the treatment of chronic myelogenous leukemia patients in chronic phase\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2402433\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon \u03b1-2b for the treatment of chronic myelogenous leukemia patients in chronic phase\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"573\";s:8:\"\u0000*\u0000epage\";s:3:\"580\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MALOISEL\";s:10:\"\u0000*\u0000aufirst\";s:1:\"F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:25:{i:0;s:9:\"GUERCI, A\";i:1;s:13:\"ABGRALL, J. F\";i:2;s:21:\"PEGOURIE-BANDELIER, B\";i:3;s:9:\"SOLARY, E\";i:4;s:10:\"CAMBIER, N\";i:5;s:7:\"COSO, D\";i:6;s:12:\"VILQUE, J. P\";i:7;s:9:\"DELAIN, M\";i:8;s:16:\"HAROUSSEAU, J. L\";i:9;s:12:\"ROUSSELOT, P\";i:10;s:10:\"BELHADJ, K\";i:11;s:10:\"GUYOTAT, D\";i:12;s:9:\"MORICE, P\";i:13;s:8:\"ATTAL, J\";i:14;s:9:\"CHABIN, M\";i:15;s:11:\"CHASTANG, C\";i:16;s:10:\"GUILHOT, J\";i:17;s:10:\"GUILHOT, F\";i:18;s:8:\"IFRAH, N\";i:19;s:12:\"MICHALLET, M\";i:20;s:11:\"REIFFERS, J\";i:21;s:10:\"TERTAIN, G\";i:22;s:8:\"BLANC, M\";i:23;s:10:\"BAUDUER, F\";i:24;s:9:\"BRIERE, J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon \u03b1-2b for the treatment of chronic myelogenous leukemia patients in chronic phase\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
